SCHEMBL352080

SCHEMBL352080

O=C(NC1=CC(=O)C2OC2C1O)c1cc2cc[nH]c2cc1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARK7 Q99497 1/20 0.51
PTPRC P08575 1/20 0.36
PTPN2 P17706 1/20 0.36
PTPN1 P18031 1/20 0.36
PTPRB P23467 1/20 0.36
PTPRE P23469 1/20 0.36
PTPN6 P29350 1/20 0.36
CFTR P13569 4/20 0.35
GABRA1 P14867 1/20 0.35
GABRB1 P18505 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
GABRB2 P47870 1/20 0.35
GABRA4 P48169 1/20 0.35
GABRA6 Q16445 1/20 0.35
NPC1 O15118 5/20 0.33
RAB9A P51151 5/20 0.33
MAPT P10636 2/20 0.33
RXFP2 Q8WXD0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL666087 0.84 PARK7 (0.64) PARK7NPC1RAB9AMAPTMEN1
SCHEMBL353426 0.80 PARK7 (0.46) PARK7NPC1RAB9AMAPTKMT2A
SCHEMBL116115 0.79 PARK7 (0.53) PARK7NPC1RAB9AMAPTMEN1
SCHEMBL666669 0.79 PARK7 (0.53) PARK7NPC1RAB9AMAPTMEN1
SCHEMBL665474 0.78 PARK7 (0.49) PARK7NPC1RAB9AMAPTMEN1
SCHEMBL664798 0.77 PARK7 (0.56) PARK7NPC1RAB9AMAPTMEN1
Dehydroxymethylepoxyquinomicin SCHEMBL14504317 0.77 PARK7 (0.54) PARK7NPC1RAB9AMAPTMEN1
Dehydroxymethylepoxyquinomicin SCHEMBL1671089 0.77 PARK7 (0.54) PARK7NPC1RAB9AMAPTMEN1
Dehydroxymethylepoxyquinomicin SCHEMBL1669417 0.77 PARK7 (0.54) PARK7NPC1RAB9AMAPTMEN1
Dehydroxymethylepoxyquinomicin SCHEMBL14491796 0.77 PARK7 (0.54) PARK7NPC1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP claimed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US claimed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US claimed
EP-2411376-B1 INHIBITORS OF NF-KB PROFECTUS BIOSCIENCES INC (US) 2015-04-22 EP disclosed
US-8629164-B2 Inhibitors of NF-κB PROFECTUS BIOSCIENCES, INC. (US) 2014-01-14 US disclosed
US-20120015952-A1 Inhibitors of NF-KB PROFECTUS BIOSCIENCES, INC. (US) 2012-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120015952-A1 Inhibitors of NF-KB NFKBIA, IKBKB, IKBKG PARK7 3327/4885PTPRC 1056/4885PTPN2 1040/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.